Business
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health & Biologicals (“Proliant”), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announ
About this update from Dyadic International, Inc.
[{"type":"image","alt":"Dyadic International, Inc.","displaySize":"","headline":null,"caption":"Dyadic International, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":180,"url":"https://media.zenfs.com/en/globenewswire.com/2a288e59b65031a67c22f5fb4925ffb4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PBlJ.1nJfXGJZqZFhMHG6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2a288e59b65031a67c22f5fb4925ffb4","width":300,"height":180}},"lazy":false},{"type":"text","content":"JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health & Biologicals (“Proliant”), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announced the commercial launch of AlbuFree™ DX, a recombinant human albumin (rHA) product produced using Dyadic’s proprietary filamentous fungal expression technology.","length":666,"tagName":"p"},{"type":"text","content":"The launch of AlbuFree™ DX underscores Dyadic’s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the terms of the agreement, Dyadic will receive a share of profits from Proliant’s commercial sales of recombinant human albumin products.","length":331,"tagName":"p"},{"type":"text","content":"“This launch is a clear validation of Dyadic’s technology and our commercialization strategy,” said Joe Hazelton, President and Chief Operating Officer of Dyadic. “Recombinant human albumin is a well-understood product with broad adoption in cell culture and life science applications, making it an ideal fit for our platform and partner-driven commercialization model.”","length":370,"tagName":"p"},{"type":"text","content":"Recombinant human albumin is a critical component in cell culture media and other life science applications, where demand is rising for animal-free, scalable, and supply-secure inputs. The launch of AlbuFree™ DX marks the first major commercial step in Dyadic’s growing portfolio of market-s...